The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Tufts Center for the Study of Drug Development (CSDD) recently completed research, titled “Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing” that compared cycle times and development economics between multi- and single-source CDMO models. While there are many studies that debate the total cost of drug development,1-3 the Tufts study sought a better understanding of which model offered the most accelerated time-to-market for its clients. By focusing on time as a primary value driver, a sponsor can lower the overall cost of bringing its drug to market, and more importantly, achieve the speed-to-market patients both want and need.